Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

NCT05281510 PHASE2 COMPLETED Results posted

The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).

Details

Lead sponsor	Gilead Sciences
Phase	PHASE2
Status	COMPLETED
Enrolment	20
Start date	Thu Jun 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• HIV-1-infection

Interventions

• Vesatolimod
• VRC07523LS
• CAP256V2LS

Countries

South Africa